ArticleFrontiers in oncology2026
Case Report: AFP-producing gastric hepatoid adenocarcinoma with multiple liver metastases - integrating quantitative imaging and diagnostic decision analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatoid adenocarcinoma of the stomach (HAS) is a rare and aggressive gastric cancer variant with both glandular and hepatocellular differentiation. The AFP-producing subtype is strongly associated with early liver metastasis and poor prognosis, presenting significant diagnostic challenges due to its resemblance to hepatocellular carcinoma (HCC). Case summary: A 68-year-old male presented with progressive dizziness and fatigue. Initial contrast-enhanced abdominal CT revealed a hypervascular gastric antral mass with quantitative enhancement values of 52 ± 3 HU (arterial), 78 ± 5 HU (portal), and 85 ± 4 HU (delayed) in the submucosal layer. Serum AFP was markedly elevated at 918.88 ng/mL. Gastroscopic biopsy confirmed AFP-producing HAS. The patient underwent Billroth II gastrectomy. Four months postoperatively, surveillance CT identified multiple new hypervascular liver metastases, prompting right hepatectomy followed by adjuvant radiochemotherapy. At three-month follow-up, the patient was asymptomatic with normalized tumor markers. Conclusion: This case illustrates the utility of quantitative CT enhancement analysis for characterizing the hypervascular phenotype of AFP-producing HAS and proposes a conceptual diagnostic framework to differentiate HAS from HCC. Multidisciplinary collaboration and systematic serum AFP screening in patients with gastric lesions are essential for optimal management of this aggressive malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.